T Bulut1, R Oosterhof-Berktas2, R H Geelkerken3, M Brusse-Keizer4, E J Stassen5, J J Kolkman6. 1. Department of Radiology, Medisch Spectrum Twente, Enschede, The Netherlands. Electronic address: t.bulut@mst.nl. 2. Department of Radiology, Medisch Spectrum Twente, Enschede, The Netherlands; Department of Radiology Martini Ziekenhuis, Groningen, The Netherlands. 3. Department of Vascular Surgery, Medisch Spectrum Twente, Enschede, The Netherlands; Faculty Science and Technology, Experimental Centre of Technical Medicine, University of Twente, Enschede, The Netherlands. 4. Department of Epidemiology, Medisch Spectrum Twente, Enschede, The Netherlands. 5. Department of Radiology, Medisch Spectrum Twente, Enschede, The Netherlands. 6. Department of Gastroenterology, Medisch Spectrum Twente, Enschede, The Netherlands; Department of Gastroenterology University Medical Centre, Groningen, The Netherlands.
Abstract
INTRODUCTION: Over the past decade, primary percutaneous mesenteric artery stenting (PMAS) has become an alternative to open revascularisation for treatment of mesenteric ischaemia. Institutes have presented favourable short-term outcomes after PMAS, but there is a lack of data on long-term stent patency. METHODS: One hundred and forty-one patients treated by PMAS for acute and chronic mesenteric ischaemia over an 8 year period were studied. Anatomical success was assessed by duplex ultrasound and/or CT angiography. A stenosis ≥70% was considered to be a failure. RESULTS: Eighty-six coeliac arteries (CA) and 99 superior mesenteric arteries (SMA) were treated with PMAS in 141 patients. Nine CAs (10%) and 30 SMAs (30%) were occluded at the time of treatment. Median follow-up was 32 months (IQR 20-46). The overall primary patency rate at 12 and 60 months was 77.0% and 45.0%. The overall primary assisted patency rate was 90.3% and 69.8%. Overall secondary patency was 98.3% and 93.6%. CONCLUSION: This study shows excellent long-term secondary patencies after PMAS, comparable with published data on long-term patencies after open surgical revascularisation.
INTRODUCTION: Over the past decade, primary percutaneous mesenteric artery stenting (PMAS) has become an alternative to open revascularisation for treatment of mesenteric ischaemia. Institutes have presented favourable short-term outcomes after PMAS, but there is a lack of data on long-term stent patency. METHODS: One hundred and forty-one patients treated by PMAS for acute and chronic mesenteric ischaemia over an 8 year period were studied. Anatomical success was assessed by duplex ultrasound and/or CT angiography. A stenosis ≥70% was considered to be a failure. RESULTS: Eighty-six coeliac arteries (CA) and 99 superior mesenteric arteries (SMA) were treated with PMAS in 141 patients. Nine CAs (10%) and 30 SMAs (30%) were occluded at the time of treatment. Median follow-up was 32 months (IQR 20-46). The overall primary patency rate at 12 and 60 months was 77.0% and 45.0%. The overall primary assisted patency rate was 90.3% and 69.8%. Overall secondary patency was 98.3% and 93.6%. CONCLUSION: This study shows excellent long-term secondary patencies after PMAS, comparable with published data on long-term patencies after open surgical revascularisation.
Authors: Andrew S Miller; Kathryn Boyce; Benjamin Box; Matthew D Clarke; Sarah E Duff; Niamh M Foley; Richard J Guy; Lisa H Massey; George Ramsay; Dominic A J Slade; James A Stephenson; Phil J Tozer; Danette Wright Journal: Colorectal Dis Date: 2021-02 Impact factor: 3.917
Authors: Louisa Jd van Dijk; Desirée van Noord; Annemarie C de Vries; Jeroen J Kolkman; Robert H Geelkerken; Hence Jm Verhagen; Adriaan Moelker; Marco J Bruno Journal: United European Gastroenterol J Date: 2018-12-04 Impact factor: 4.623
Authors: Louisa J D van Dijk; Jihan Harki; Desirée van Noord; Hence J M Verhagen; Jeroen J Kolkman; Robert H Geelkerken; Marco J Bruno; Adriaan Moelker Journal: Trials Date: 2019-08-20 Impact factor: 2.279
Authors: Alicja Zientara; Anja-Rebeka Domenghino; Igor Schwegler; Hans Bruijnen; Annelies Schnider; Markus Weber; Stefan Gutknecht; Nicolas Attigah Journal: BMC Surg Date: 2021-02-18 Impact factor: 2.102